Furthermore, a study by Moon et al. developed a dual-action lipid nanoparticle (dual-LNP) co-delivering VISTA-specific siRNA and a TLR9 agonist, effectively enhancing anti-tumor immunity in murine models. This evidence concerns the gene TLR9 and neoplasm.